Dr Sultan also recommends physician developed supporting supplements that enhance GLP 1 therapy and promote overall metabolic health

Theoretical risks are extrapolated from IGF-1 biology: Hypoglycemia : IGF-1 shares structural homology with insulin and can activate insulin receptors, particularly at high concentrations Growth factor signaling : Sustained IGF-1R activation carries theoretical oncogenic potential, as the IGF-1 axis promotes cell proliferation and survival Systemic effects : Reduced IGFBP binding means greater systemic exposure to active growth factor, potentially amplifying both therapeutic and adverse effects Organ-specific : Potential for cardiac hypertrophy and other tissue growth with chronic exposure MGF Side Effects# MGF safety data are limited to preclinical observations: Rapid clearance : The very short half-life limits systemic exposure, which may reduce off-target effects Local action : Endogenous MGF acts primarily as a local paracrine factor, suggesting that targeted administration may have a favorable safety profile No human data : Without clinical trials, the safety profile in humans remains undefined Proliferative concerns : As a satellite cell activator, theoretical concerns exist regarding uncontrolled proliferation, though preclinical data have not demonstrated this Dosing and Administration Comparison# IGF-1 LR3 Dosing# MGF Dosing# The short half-life of native MGF is a significant practical limitation

Pen-sharing poses a risk for transmission of blood-borne pathogens
By understanding the science and respecting the timing, you put yourself in the best possible position to observe the true effects of these fascinating compounds
Claims vs Reality After the Vote What Happens Next at FDA FDA reviews the meeting record After the meeting, FDA can review the committee vote, member explanations, staff analysis, public testimony, written docket comments, and other submitted material